구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 5-aminosalicylic acid (5-aminosalicylic acid) Merck Sharp & Dohme LLC·Colitis, Ulcerative 109 trials·t½ 8.2 h |
|---|---|
Overview Program | 5-aminosalicylic acid |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Colitis, Ulcerative |
Overview Indication | Colitis, Ulcerative |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target protective effects against experimental colitis by modulating inflammation, supporting barrier integrity, and regulating key signaling pathway |
MoA Biomarker | Biomarker-Guided, Patient-Centered Approach |
PK/PD Half-life | 8.2 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PK |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Switching from sulphasalazine or oral 5-aminosalicylic acid to another oral 5-aminosalicylic acid drug in the maintenance of remission in ulcerative colitis.. This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the probability of failure to maintain clinical remission, endoscopic remission, or both, following a switch from SASP or oral 5-ASA drug (comp… |
Clinical Safety signal | Switching from sulphasalazine or oral 5-aminosalicylic acid to another oral 5-aminosalicylic acid drug in the maintenance of remission in ulcerative colitis.. This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the probability of failure to maintain clinical remission, endoscopic remission, or both, following a switch from SASP or oral 5-ASA drug (comp… |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 5-aminosalicylic acid (5-aminosalicylic acid) Merck Sharp & Dohme LLC·Colitis, Ulcerative 109 trials·t½ 8.2 h |
|---|---|
Overview Program | 5-aminosalicylic acid |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | Colitis, Ulcerative |
Overview Indication | Colitis, Ulcerative |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target protective effects against experimental colitis by modulating inflammation, supporting barrier integrity, and regulating key signaling pathway |
MoA Biomarker | Biomarker-Guided, Patient-Centered Approach |
PK/PD Half-life | 8.2 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | PK |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Switching from sulphasalazine or oral 5-aminosalicylic acid to another oral 5-aminosalicylic acid drug in the maintenance of remission in ulcerative colitis.. This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the probability of failure to maintain clinical remission, endoscopic remission, or both, following a switch from SASP or oral 5-ASA drug (comp… |
Clinical Safety signal | Switching from sulphasalazine or oral 5-aminosalicylic acid to another oral 5-aminosalicylic acid drug in the maintenance of remission in ulcerative colitis.. This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the probability of failure to maintain clinical remission, endoscopic remission, or both, following a switch from SASP or oral 5-ASA drug (comp… |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교